|
|
|
|
|
|
|
|
|
|
"Twelve patients entered the study, and accrual was terminated in the first stage because of lack of response or disease stabilization beyond 6 months."
Wednesday, January 13, 2010
Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
"Twelve patients entered the study, and accrual was terminated in the first stage because of lack of response or disease stabilization beyond 6 months."
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.